NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/N1 Implant
intracorticalIDEinvestigational

N1 Implant

Implant Type
intracortical
Electrodes
1,024
Channels
64
FDA Status
IDE
Clinical Stage
PRIME Feasibility Study
Status
investigational
About

The N1 is Neuralink's first human-implantable BCI, a coin-sized device containing 1,024 electrodes distributed across 64 flexible polymer threads, each thinner than a human hair. The chip is implanted flush with the skull surface by the R1 surgical robot, which precisely inserts the threads into the motor cortex while avoiding surface vasculature. The N1 streams full-band neural signals wirelessly via Bluetooth Low Energy and is inductively recharged through the scalp. First implanted in a human on January 28, 2024, the device targets individuals with paralysis due to ALS or spinal cord injury, enabling computer cursor control and communication via decoded motor intent.

Target Conditions
ALSquadriplegiaspinal cord injuryblindness
Milestones
2020-08First public demonstration in pig (Gertrude)
2021-04Monkey (Pager) plays Pong via neural signals
2023-05FDA grants Investigational Device Exemption for human trials
2024-01-28First human implant — Noland Arbaugh, ALS patient
2024-03Noland achieves 8+ hours/day device use; chess at 4000 Elo; 62 WPM typing
2024-08Second human patient (Alex) implanted
2025-01Third human patient implanted; expanded PRIME enrollment
FDA Regulatory Pathway
Investigational Device Exemption (IDE)

An IDE permits a device to be used in a clinical study to collect safety and effectiveness data required for a PMA or 510(k) submission. IDE devices are not approved for commercial sale.

FDA Device Regulatory Guidance ↗
Other intracortical Devices